Jun Hata1, Hisatomi Arima, Peter M Rothwell, Mark Woodward, Sophia Zoungas, Craig Anderson, Anushka Patel, Bruce Neal, Paul Glasziou, Pavel Hamet, Giuseppe Mancia, Neil Poulter, Bryan Williams, Stephen Macmahon, John Chalmers. 1. From The George Institute for Global Health, University of Sydney, Sydney, Australia (J.H., H.A., M.W., S.Z., C.A., A.P., B.N., S.M., J.C.); University of Oxford, Oxford, United Kingdom (P.M.R., S.M.); School of Public Health, Monash University, Clayton, Australia (S.Z.); Bond University, Gold Coast, Australia (P.G.); Université de Montréal, Montreal, Canada (P.H.); University of Milan-Bicocca, Milan, Italy (G.M.); Imperial College, London, United Kingdom (N.P.); and University College London (UCL) and the National Institute for Health Research UCL Hospitals Biomedical Research Centre, London, United Kingdom (B.W.).
Abstract
BACKGROUND: Recent evidence suggests that visit-to-visit variability in systolic blood pressure (SBP) and maximum SBP are predictors of cardiovascular disease. However, it remains uncertain whether these parameters predict the risks of macrovascular and microvascular complications in patients with type 2 diabetes mellitus. METHODS AND RESULTS: The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) was a factorial randomized controlled trial of blood pressure lowering and blood glucose control in patients with type 2 diabetes mellitus. The present analysis included 8811 patients without major macrovascular and microvascular events or death during the first 24 months after randomization. SBP variability (defined as standard deviation) and maximum SBP were determined during the first 24 months after randomization. During a median 2.4 years of follow-up from the 24-month visit, 407 major macrovascular (myocardial infarction, stroke, or cardiovascular death) and 476 microvascular (new or worsening nephropathy or retinopathy) events were observed. The association of major macrovascular and microvascular events with SBP variability was continuous even after adjustment for mean SBP and other confounding factors (both P<0.05 for trend). Hazard ratios (95% confidence intervals) for the highest tenth of SBP variability were 1.54 (0.99-2.39) for macrovascular events and 1.84 (1.19-2.84) for microvascular events in comparison with the lowest tenth. For maximum SBP, hazard ratios (95% confidence intervals) for the highest tenth were 3.64 (1.73-7.66) and 2.18 (1.04-4.58), respectively. CONCLUSION: Visit-to-visit variability in SBP and maximum SBP were independent risk factors for macrovascular and microvascular complications in type 2 diabetes mellitus. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov.
BACKGROUND: Recent evidence suggests that visit-to-visit variability in systolic blood pressure (SBP) and maximum SBP are predictors of cardiovascular disease. However, it remains uncertain whether these parameters predict the risks of macrovascular and microvascular complications in patients with type 2 diabetes mellitus. METHODS AND RESULTS: The Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) was a factorial randomized controlled trial of blood pressure lowering and blood glucose control in patients with type 2 diabetes mellitus. The present analysis included 8811 patients without major macrovascular and microvascular events or death during the first 24 months after randomization. SBP variability (defined as standard deviation) and maximum SBP were determined during the first 24 months after randomization. During a median 2.4 years of follow-up from the 24-month visit, 407 major macrovascular (myocardial infarction, stroke, or cardiovascular death) and 476 microvascular (new or worsening nephropathy or retinopathy) events were observed. The association of major macrovascular and microvascular events with SBP variability was continuous even after adjustment for mean SBP and other confounding factors (both P<0.05 for trend). Hazard ratios (95% confidence intervals) for the highest tenth of SBP variability were 1.54 (0.99-2.39) for macrovascular events and 1.84 (1.19-2.84) for microvascular events in comparison with the lowest tenth. For maximum SBP, hazard ratios (95% confidence intervals) for the highest tenth were 3.64 (1.73-7.66) and 2.18 (1.04-4.58), respectively. CONCLUSION: Visit-to-visit variability in SBP and maximum SBP were independent risk factors for macrovascular and microvascular complications in type 2 diabetes mellitus. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov.
Authors: Jeff Whittle; Amy I Lynch; Rikki M Tanner; Lara M Simpson; Barry R Davis; Mahboob Rahman; Paul K Whelton; Suzanne Oparil; Paul Muntner Journal: Clin J Am Soc Nephrol Date: 2016-02-18 Impact factor: 8.237
Authors: Meghan B Brennan; Marylou Guihan; Elly Budiman-Mak; Hyojung Kang; Jennifer M Lobo; Bryn L Sutherland; Nicholas Emanuele; Elbert S Huang; Min-Woong Sohn Journal: J Hypertens Date: 2018-11 Impact factor: 4.844
Authors: Keith M Diaz; Rikki M Tanner; Louise Falzon; Emily B Levitan; Kristi Reynolds; Daichi Shimbo; Paul Muntner Journal: Hypertension Date: 2014-07-28 Impact factor: 10.190
Authors: Iciar Martín-Timón; Cristina Sevillano-Collantes; Amparo Segura-Galindo; Francisco Javier Del Cañizo-Gómez Journal: World J Diabetes Date: 2014-08-15
Authors: Adam de Havenon; Nora F Fino; Brian Johnson; Ka-Ho Wong; Jennifer J Majersik; David Tirschwell; Natalia Rost Journal: Stroke Date: 2019-09-20 Impact factor: 7.914
Authors: Chike C Nwabuo; Yuichiro Yano; Henrique T Moreira; Duke Appiah; Henrique D Vasconcellos; Queen N Aghaji; Anthony Viera; Jamal S Rana; Ravi V Shah; Venkatesh L Murthy; Norrina B Allen; Pamela J Schreiner; Donald M Lloyd-Jones; João A C Lima Journal: JAMA Cardiol Date: 2020-07-01 Impact factor: 14.676